The objective of the OrganOx metra® New Enrollment Post-Approval Study is to collect data on the post-transplant clinical outcomes of DBD and DCD donor livers preserved and assessed on the OrganOx according to the current indications for use in the real-world setting.

开始日期2022-11-10

申办/合作机构

OrganOx Ltd.

NCT04862156 / TerminatedN/A

Continued Access Protocol Study for the Use of the OrganOx Metra Normothermic Machine Perfusion Device in Human Liver Transplantation

The single-arm continued access phase will be used to collect additional effectiveness and safety data to support the objectives and outcomes of the original IDE pivotal study.

开始日期2021-10-10

申办/合作机构

OrganOx Ltd.

[+1]

NCT04483102 / RecruitingN/AIIT

A Prospective, Single-Center, Non-Randomized, Clinical Trial of Transplantation of Discarded Livers Using Normothermic Machine Perfusion (NMP)

This is a prospective, non-randomized, clinical trial of discarded liver transplants that have received normothermic machine perfusion (NMP), compared with standard cold preservation liver transplants. The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. Liver transplant outcomes will be ascertained during 12 months post-transplantation. The results of the trial will be compared with those of contemporary comparison groups of patients who received the standard criteria donor liver transplantation.

开始日期2020-12-03

申办/合作机构

Washington University School of Medicine

[+2]

100 项与 OrganOx Ltd. 相关的临床结果

登录后查看更多信息

0 项与 OrganOx Ltd. 相关的专利（医药）

登录后查看更多信息

项与 OrganOx Ltd. 相关的文献（医药）

2019-06-01·Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society1区 · 医学

A Back‐to‐Base Experience of Human Normothermic Ex Situ Liver Perfusion: Does the Chill Kill?

1区 · 医学

Article

作者: Friend, Peter J ; Bigam, David ; Bral, Mariusz ; Leon Izquierdo, Dayne ; Shapiro, A M James ; Dajani, Khaled ; Kneteman, Norman ; Ceresa, Carlo D L

Normothermic machine perfusion (NMP) has been shown to protect livers from injury between procurement and transplantation in a randomized controlled trial, where the machine was transported to and from the donor center. The aim of this study was to determine whether an alternative, more practical back‐to‐base approach after initial static cold storage would compromise beneficial outcomes. Between February 2015 and June 2018, a nonrandomized pilot study was performed at a single site. Outcomes of back‐to‐base livers (n = 26) were compared with those of grafts procured locally that underwent immediate NMP (n = 17). The primary outcome measure (safety) was defined as 30‐day patient and graft survival. A total of 46 liver grafts were perfused with NMP, of which 3 were discarded based on poor ex situ perfusion function. The 30‐day patient and graft survival in the back‐to‐base and local NMP groups were both 100% (primary outcome: safety). Despite significantly prolonged mean cold ischemia time (6 versus 3.2 hours; P = 0.001), the back‐to‐base livers demonstrated no difference in graft function, incidence of complications, or graft and patient survival. In conclusion, the back‐to‐base approach was safe, did not compromise the overall benefit of NMP, and offers a practical alternative to portable normothermic ex situ machine transport.

2019-06-01·American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons1区 · 医学

In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival

1区 · 医学

Article

作者: Fear, Corrina ; Wigmore, Stephen J ; Taylor, Rhiannon ; Allen, Elisa ; Sutherland, Andrew ; Oniscu, Gabriel C ; Messer, Simon ; Upponi, Sara ; Randle, Lucy V ; Hunt, Fiona ; Large, Stephen ; Watson, Christopher J E ; Cornateanu, Sorina ; Crick, Keziah ; Terrace, John D ; Butler, Andrew J ; Currie, Ian

Livers from controlled donation after circulatory death (DCD) donors suffer a higher incidence of nonfunction, poor function, and ischemic cholangiopathy. In situ normothermic regional perfusion (NRP) restores a blood supply to the abdominal organs after death using an extracorporeal circulation for a limited period before organ recovery. We undertook a retrospective analysis to evaluate whether NRP was associated with improved outcomes of livers from DCD donors. NRP was performed on 70 DCD donors from whom 43 livers were transplanted. These were compared with 187 non-NRP DCD donor livers transplanted at the same two UK centers in the same period. The use of NRP was associated with a reduction in early allograft dysfunction (12% for NRP vs. 32% for non-NRP livers, P = .0076), 30-day graft loss (2% NRP livers vs. 12% non-NRP livers, P = .0559), freedom from ischemic cholangiopathy (0% vs. 27% for non-NRP livers, P < .0001), and fewer anastomotic strictures (7% vs. 27% non-NRP, P = .0041). After adjusting for other factors in a multivariable analysis, NRP remained significantly associated with freedom from ischemic cholangiopathy (P < .0001). These data suggest that NRP during organ recovery from DCD donors leads to superior liver outcomes compared to conventional organ recovery.

2019-01-01·American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons1区 · 医学

Twenty-four–hour normothermic perfusion of discarded human kidneys with urine recirculation

1区 · 医学

Article

作者: Soares, Maria F ; Roberts, Ian S ; Friend, Peter J ; Mikov, Nikolay ; Cook, Andrew ; Weissenbacher, Annemarie ; Boubriak, Olga ; Coussios, Constantin C ; Hunter, James P ; Ploeg, Rutger J ; Voyce, Daniel ; Lo Faro, Letizia

Transportable normothermic kidney perfusion for 24 hours or longer could enable viability assessment of marginal grafts, increased organ use, and improved transplant logistics. Eleven clinically declined kidneys were perfused normothermically, with 6 being from donors after brain death (median cold ischemia time 33 ± 36.9 hours) and 5 being from donors after circulatory death (36.2 ± 38.3 hours). Three kidneys were perfused using Ringer's lactate to replace excreted urine volume, and 8 kidneys were perfused using urine recirculation to maintain perfusate volume without fluid replenishment. In all cases, normothermic perfusion either maintained or slightly improved the histopathologically assessed tubular condition, and there was effective urine production in kidneys from both donors after brain death and donors after circulatory death (2367 ± 1798 mL vs 744.4 ± 198.4 mL, respectively; P = .44). Biomarkers, neutrophil gelatinase-associated lipocalin, and kidney injury molecule-1 were successfully detected and quantified in the perfusate. All kidneys with urine recirculation were readily perfused for 24 hours (n = 8) and exhibited physiological perfusate sodium levels (140.7 ± 1.2 mmol/L), while kidneys without urine recirculation (n = 3) achieved a reduced normothermic perfusion time of 7.7 ± 1.5 hours and significantly higher perfusate sodium levels (159.6 ± 4.63 mmol/:, P < .01). Normothermic machine perfusion of human kidneys for 24 hours appears to be feasible, and urine recirculation was found to facilitate the maintenance of perfusate volume and homeostasis.

项与 OrganOx Ltd. 相关的新闻（医药）

2024-11-12

·GlobeNewswire-Health Care

OrganOx and eGenesis Announce Exclusive Clinical Co-Development Agreement for Treatment of Patients with Liver Failure in the Acute Setting

Partnership aims to advance a novel liver support system integrating a leading organ preservation platform with whole biologic livers to address a major unmet needOXFORD, United Kingdom and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- OrganOx Ltd., a medical technology company developing innovative solutions for organ preservation, and eGenesis, Inc., a biotechnology company developing human-compatible organs for patients with organ failure, announced today an exclusive clinical co-development agreement to advance a liver support system to facilitate liver recovery in the acute setting. OrganOx’s normothermic machine perfusion (NMP) technology will be combined with eGenesis’ human-compatible, genetically engineered porcine livers to treat patients with liver failure. The companies will focus on the estimated 35,000 patients in the United States hospitalized each year for acute or acute-on-chronic liver failure1,2. The efficacy of existing liver support options is limited, and patients in liver failure face mortality rates as high as 50 percent2. For some patients, utilizing a human compatible, genetically engineered porcine liver to support the function of a patient’s decompensated liver may provide time for the recovery of the patient’s native liver or time to obtain a liver transplant. Based on positive clinical data demonstrated in these initial patient populations, the companies may explore the use of this system for the over 300,000 additional patients admitted annually to hospital in the United States in the acute setting with other forms of liver failure3. Earlier this year, the companies announced a proof of concept demonstration of the approach and have now successfully completed three such experiments as part of the PERFUSE-2 study4, evaluating the feasibility of using this perfusion system to support patients suffering from liver failure. The perfusions were performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) system. eGenesis and OrganOx anticipate submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in 2025 to initiate a Phase 1 clinical study. “Our expanded partnership, and now exclusive co-development agreement with eGenesis, not only strengthens our relationship but also demonstrates our confidence in the technology we're jointly advancing,” said Craig Marshall, CEO of OrganOx. “This co-development further exemplifies our mission to improve treatment options for patients with organ failure.” The OrganOx ELC system combines automated NMP technology with a patient support accessory device to provide support for a patient’s liver function. “We are excited to partner with OrganOx to address a critical unmet need for patients with liver failure,” said Michael Curtis, Ph.D., CEO of eGenesis. “This collaboration is a crucial step in our mission to develop safe and effective human-compatible organs for patients suffering from organ failure.” The EGEN-5784 liver carries three classes of edits: (1) knock out of three genes involved in the synthesis of glycan antigens implicated in hyperacute rejection, (2) insertion of seven human transgenes involved in the regulation of several pathways that modulate rejection: inflammation, innate immunity, coagulation, and complement, and (3) inactivation of the endogenous retroviruses in the porcine genome. About OrganOxOrganOx is a commercial stage organ technology company, spun out of the University of Oxford in 2008. The company’s first product, the OrganOx metra® normothermic machine perfusion (NMP) system for liver transplantation, has been used to support more than 4,000 liver transplant operations globally, optimizing the use of donated organs by enabling assessment of the quality of livers as well as longer preservation durations. Learn more at www.organox.com. About eGenesiseGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs. The eGenesis Genome Engineering and Production (EGEN™) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering. eGenesis has demonstrated durable preclinical success to date and is advancing development programs for acute liver failure, kidney transplant, and pediatric as well as adult heart transplant. Learn more at www.egenesisbio.com. Contacts OrganOx Investor Relations:Steve DeitschChief Financial Officer, OrganOxinvestorrelations@organox.com OrganOx Media:Emma YangHealth+Commerceemma@healthandcommerce.com eGenesis Media:Kimberly HaKimberly.ha@egenesisbio.com References Stravitz, R.T. et al. (2023) Future directions in acute liver failure. Hepatology, 78(4), pp. 1266–1289. https://doi-org.libproxy1.nus.edu.sg/10.1097/hep.0000000000000458.Allen, A.M., et al. (2016). Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology, 64(6), pp.2165–2172. https://doi-org.libproxy1.nus.edu.sg/10.1002/hep.28812.Jinjuvadia, R. and Liangpunsakul, S. (2014) Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States. Journal of Clinical Gastroenterology, 49(6), pp. 506–511. https://doi-org.libproxy1.nus.edu.sg/10.1097/mcg.0000000000000161.OrganOx (2024). Successful Use of a Genetically Engineered Porcine Liver with a Human Donor. January 18th, 2024. Available at: https://www.organox.com/news/view/successful-use-of-a-genetically-engineered-porcine-liver-with-a-human-donor.

2024-10-26

·动脉网

一年三起活体异种器官植入手术，器官移植大爆发？

今年5月，安徽医科大学第一附属医院和云南农业大学合作，成功将经过基因改造的猪肝脏移植到了一位肝癌重症患者身上。术后第七天，患者已能下地自由活动，没有发现超急性和急性排斥反应，凝血系统无障碍，肝功能已恢复正常。移植猪肝方面，每天有200ml左右金黄色胆汁分泌，CT和B超证实移植猪肝脏肝动脉、门静脉、肝静脉血流完全正常。这是全球第五起活体异种器官移植，仅2024年便发生了其中的三起。 2022—2024年发生的5起活体异体器官移植活体实验外，死亡人体相关的移植试验也在加速进行。今年3月，空军军医大学西京医院团队将多基因编辑猪的全肝与肾脏分别移植到了两位脑死亡人体内，术后均在一定时间内实现正常运转。昆明医科大学第一附属医院同样找到了云南农业大学，开展了一起从猪到脑死亡人体的肝肾联合异种移植实验，同样取得了不错的进展。爆发的临床试验之下，器官移植似乎已经走到了技术迁跃的边缘。 01 如何补足超200万的器官移植缺？广义上的器官移植不局限于动物到人体的移植，还包括技术已经相对成熟的人到人体，即将有活力的供体器官通过手术转移至患者体内，以替代已经丧失功能的器官。目前，我们的大部分器官已能实现移植，如心脏、肺、肝、肾脏、胰、小肠、皮肤等。此外，角膜和血管等组织的移植也已在临床中广泛应用。不过，当下的器官移植产业远谈不上成熟。以最为常见的“换肾”为例，当双侧肾脏功能均丧失时，或是慢性肾功能不全发展至终末期，肾脏移植都是可行情况下的首选治疗方案。此外，相比腹膜、血液透析，肾移植在长期存活率、生存质量和治疗成本等方面均有明显优势。但由于肾移植主要是通过配型的方法来进行，匮乏的肾源与不成功的配型下，很多患者直到病逝也未能等到治疗机会。参考国际器官捐献与移植注册数据，2020年底有超过34.54万名患者仍在等待器官移植，仅在公布数据的那一年，等候名单中便有23103名患者，因未等到肾源遗憾去世。还有一组数据能够更为直接地阐述现状：全球有逾266万名接受透析治疗的终末期肾病患者，仅有5.65%患者能够获得肾脏移植。应对这一挑战，全球各地都在推动产业相关法律法规的完善，建立更加透明、公正的器官捐献移植体系，通过理顺关系、明晰法律、加速传播等树立公众对于器官移植的正常认知，进而鼓励更多人群参与到器官的传递中。譬如，西班牙、法国等每百万人口器官捐献率排名靠前的国家推行的是“默认同意”，即生前未明确表示拒绝捐献者均被推定为器官捐献者；美国大部分州采用了领取驾照时登记捐献器官意愿的制度。而在国内，国务院发布的《人体器官捐献和移植条例》于今年5月1日正式施行，进一步对于器官移植行业进行规范。相比2007年施行的《人体器官移植条例》，新条例增加“捐献”二字，凸显器官捐献的重要性，强化了对器官捐献的激励与引导。与此同时，器官移植产业也在不断进化，尽可能提高离体器官的存活率。目前，主流的肝脏保存、转运的机械灌注分为常温灌注与低温灌注两种技术路径，可服务于不同的供体和治疗场景。肝脏常温机械灌注（NMP）的灌注温度维持在35-38℃，器官处于生理代谢状态，耗氧量大，灌注需使用氧合的血液制品。优势在于可以通过胆汁生成和乳酸清除率来评估肝脏质量，作为平台未来有治疗递送的应用空间；缺点在于短暂灌注中止也会造成肝脏二次缺血、血制品相关风险、操作复杂、灌注成本高。肝脏低温机械灌注（HMP）的灌注温度维持在0-12℃，低温状态下肝脏代谢受抑制。优势在于低温下肝脏对缺血的耐受度更高，缺血造成的术后胆道并发症率降低，且短暂的技术故障不会导致器官热缺血损伤、造成功能丢失；缺点在于低温下肝脏功能评估指标较NMP少。在全球已实现商业化的肝脏机械灌注设备中，Transmedics与OrganOx两家企业均应用NMP技术，XVIVO则采用可调温灌注系统。国内的健耕医疗、奇点医疗、莱普晟的机械灌注均采用HMP技术。其中，健耕医疗的 LifePort肾脏灌注运转箱被近 40 个国家和地区、数百家 OPO 或移植中心使用。美国 57 家 OPO 中的 54 家使用 LifePort的产品进行供肾机械灌注，市场占有率第一。健耕医疗LifePort产品体系奇点医疗则是与中山一院实现深度合作，推出了“无缺血肝脏灌注系统”，实现为离体器官供血供氧，在不中断血流情况下维持肝脏正常生理功能，颠覆了传统器官冰鲜保存方式，极大程度上避免了供体器官缺血再灌注损伤，显著改善移植预后，将器官移植推向了“热移植时代”。此外，该企业还将技术突破直指肾源，推出“器官拯救者”设备。该设备可利用既往手段无法实施捐献的器官——心死亡器官捐献，有望增加50%以上的器官来源，缓解器官短缺问题。 02 异种移植，器官移植的终极路径？尽管围绕离体器官存活率展开的各种创新有效提高了移植患者的五年生存率，亦在一定程度上扩展了可用活体器官的供应量。但要补足移植患者庞大的需求缺口，异种器官移植才是解决问题的根本之道。在非人灵长类动物模型的临床前研究中，肾脏和心脏被认为是最适合进行异种移植的器官。经CRISPR修饰该猪的基因组以敲除抗原编码基因，并加入人类基因并清除猪病毒，该猪肾在试验猴体内最终存活了758天。心脏方面，原位移植（移除受体心脏）的最长存活时间为264天，异位心脏移植（不移除受体本身的心脏）的最长存活时间纪录则达到了近1000天。不过，无论是上述提到的5例活体异种器官移植手术中，还是人体到人体完成的移植器官，患者的术后生存率都还不尽如人意。除去尚未披露治疗结果的安徽医科大学第一附属医院完成的异种肝移植手术，其余活体异种器官移植手术的患者最长存活时间仅为61天。USRDS 2021年度报告中阐述的同种移植手术数据显示，公民逝世后器官捐献/活体捐献的肾移植后十年生存率为49.5%/65.5%，同样存在极大的提升空间。感染是肾移植术后早期死亡最常见的原因，与术后免疫抑制过度、营养不良及术后并发症等有关。以免疫抑制过度为例，对于已经完成肾移植的患者，免疫抑制不足可能导致排斥反应，造成移植物结构损伤、移植物功能丢失、再移植困难；免疫抑制过度又会增加发生感染和肿瘤的风险。此外，常用的免疫抑制剂（如环孢素、他克莫司、咪唑立宾等）治疗效果稳定，但有不良反应多，治疗方案局限等缺点。此外，生物免疫抑制剂价格昂贵，巨大的药物治疗费用也在一定程度上阻碍了手术患者的康复进展。因此，长期、持续地关怀与照护对于此类患者非常重要，医生需要对于患者的免疫状态、移植器官状态进行持续监测和调整，尽早发现问题并干预处理。另一方面，行业也需积极探索新型免疫抑制剂，在疗效与卫生经济学方面找到新的平衡点。潜在的新型免疫抑制剂盘点相较之下，异种移植排斥反应相关的基因约有30个，排斥反应更为复杂、更难克服，同时由于免疫抑制措施比同种移植更强，反过来对人体免疫系统的影响也更大，更容易导致固有免疫系统被破坏而发生感染，可能会引发严重并发症。在全球头两例异种器官移植案例中，Revivicor公司对供体猪实施了10项基因编辑操作，剔除了三个会引发人类快速抗体介导排斥反应的基因，还将六个与人类心脏免疫排斥相关的基因——CD46、CD55、血栓调节蛋白、内皮细胞蛋白C受体、CD47和血红素加氧酶-1（HO-1）植入猪的基因组中，尽可能降低排斥反应的发生概率。基因编辑大牛George Church创立的eGenesis为全球第三例活人异种移植手术培育了转基因猪。这些猪经过了69项基因组编辑，敲除与猪细胞表面糖抗原合成相关的3个基因，转入7个与排斥反应调节相关的人类基因，以便帮助猪细胞躲过人体免疫系统的盘查。同时，该公司还灭活了供体猪中的猪内源性逆转录病毒，以降低人类感染的风险。但从结果来看，各个公司在基因编辑上的努力并未完全解决问题，异种移植排斥反应依然是阻碍异体器官移植的终极难关。面对这一挑战，新西兰的NZeno，德国的Xtransplant，国内的中科奥格、盖兰德生物等初创企业也在积极入局，进行异种移植供体猪的培养，并已取得了非凡的成果。具体而言，他们以基因编辑技术构建低免疫原性供体猪，开发可供移植的猪红细胞、皮肤、肾脏等组织器官治疗技术，同时拓展基因编辑供体猪在生物材料再生医学的应用，推动中国异体器官移植产业的发展。 03 写在最后作为医学界的三大奇迹之一，器官移植最为完整地实现了人类生命高质量延续的梦想。只是，延续并非现代医学的最终目的，数以万计的研究者、医生、患者参与其中，便是为了让未来经历移植的患者，实现真正意义上的重生。实现这样一个突破必然会经历无数次的失败，但每一次失败均有其意义所在。正如全球首例猪心脏移植手术患者David Bennett的家人所说： “我们对每一个创新时刻、每一个疯狂的梦想、每一个不眠之夜心存感激，感谢所有为这项历史性的手术付出努力的人，我们希望这个故事可以成为希望的开始，而不是结束。” 走在器官移植技术迁跃的边缘，我们或许即将见证希望本身。 *封面图片来源：123rf 如果您认同文章中的观点、信息，或想进一步讨论，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

核酸药物基因疗法

2024-10-02

·GlobeNewswire-Health Care

OrganOx metra® System Approved for Liver Transplantation in Canada

2025 commercial launch planned to expand access to this platform technologyOXFORD, England and MADISON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- OrganOx Ltd, a world-leading organ medical technology company, today announced Health Canada has approved the OrganOx metra® System for use during liver transplantation. The OrganOx metra® System is currently commercially available for liver transplantation in the U.S., the U.K., and the European Union. The company plans to commercially launch the system in Canada in 2025. The OrganOx metra® System utilizes normothermic machine perfusion, or NMP, to circulate oxygenated blood, medications, and nutrients to donated organs at normal body temperature and near physiological conditions. This innovative technology extends organ preservation time, allows pre-transplant clinical assessment of organ viability and can dramatically improve operational logistics for both transplant teams and patients.1 “We are thrilled to receive this authorization in Canada, further advancing our vision to improve clinical outcomes for liver transplant patients around the globe,” said Craig Marshall, CEO of OrganOx. “In the coming months we look forward to introducing the metra® to transplant centers across Canada.” The performance of the metra® system has been evaluated across several clinical trials including the Consortium for Organ Preservation in Europe (COPE) European Trial, the first randomized trial to assess machine perfusion versus static cold storage in liver transplantation. Compared with static cold storage, the OrganOx metra® achieved a 50% lower level of graft injury despite a 54% longer mean preservation time.2 About OrganOxOrganOx is a commercial stage organ technology company with a focus on the preservation of isolated organs, spun out of the University of Oxford in 2008. The company’s first product, the OrganOx metra® normothermic machine perfusion (NMP) system for the liver, has been used to support more than 4,000 liver transplant operations globally, optimizing the use of donated organs by enabling assessment of the quality of livers as well as longer preservation durations. Other applications, including in kidney transplantation, are in development. Learn more at www.organox.com. About OrganOx metra®OrganOx metra® is a fully automated NMP device that enables continuous monitoring and evaluation of the liver, empowering surgeons to make evidence-based decisions on whether to transplant a donor organ and enabling viability testing.1 metra® is commercially available in UK (UKCA: 772261), European Union (CE Mark: MDR 772263 and MDR 772678) and the United States (FDA Approved: P200035). ContactsInvestor Relations:Steve DeitschChief Financial Officer, OrganOxinvestorrelations@organox.com Media:Emma YangHealth+Commerceemma@healthandcommerce.com References: Watson, C.J.E, Gaurav, R., Fear, C. et al. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation 106(12): 2391–2398 (2022) https://doi-org.libproxy1.nus.edu.sg/10.1097/TP.0000000000004263Nasralla, D., Coussios, C.C., Mergental, H. et al. A randomized trial of normothermic preservation in liver transplantation. Nature 557, 50–56 (2018). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41586-018-0047-9

临床研究

100 项与 OrganOx Ltd. 相关的药物交易

登录后查看更多信息

100 项与 OrganOx Ltd. 相关的转化医学

登录后查看更多信息